60 results
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
28 Mar 24
Current report (foreign)
6:02am
and small cell lung cancer, with 80-85% classified as NSCLC.2 The majority of NSCLC patients (approximately 75%) are diagnosed with advanced disease
6-K
EX-99.2
HCM
HUTCHMED (China) Limited
28 Feb 24
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
6:47am
classification. The investment in HBYS was not presented as a discontinued operation or as an asset classified as held-for-sale after the signing of the SPA … may be classified as held-for-sale even if the discontinued operations criteria are not met. The investment in HBYS was not presented
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
28 Feb 24
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
6:47am
on a graded vesting basis over the requisite service period, and accounts for forfeitures as they occur.
Share options are classified as equity-settled … awards are classified as liability-settled awards before the determination date (i.e. the date when the achievement of any performance conditions
6-K
EX-99.2
w4bt5xkh7xc1sk2 qksj
31 Jul 23
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
7:31am
6-K
EX-99.2
tq2yv 3x3v
8 Aug 22
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
6:24am
6-K
EX-99.2
dxscxy6xlkx
1 Aug 22
HUTCHMED Reports 2022 Interim Results and Provides Business Updates
7:33am
6-K
EX-99.1
gzj5uqpqgjr gcj
13 Jul 22
HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting
7:19am
6-K
EX-99.1
hom7ub5kbod
7 Mar 22
Current report (foreign)
6:19am
6-K
EX-99.2
tanwc2l fd
3 Mar 22
HUTCHMED Reports 2021 Full Year Results and Provides Business Updates
9:00am
6-K
EX-99.1
2mj 7gn3dak9kkeo1z8o
3 Mar 22
HUTCHMED Reports 2021 Full Year Results and Provides Business Updates
9:00am
6-K
EX-99.1
our1dk7 671
24 Nov 21
Current report (foreign)
6:13am
6-K
EX-99.1
gxe8r1t17e ws2r19957
20 Sep 21
Current report (foreign)
6:27am
6-K
EX-99.1
xxle9xt
8 Sep 21
Current report (foreign)
7:35am
6-K
EX-99.2
crncr0tl tx
28 Jul 21
HUTCHMED Reports 2021 Interim Results and Provides Business Updates
8:17am
6-K
EX-99.1
jytjwmmw5yjal
16 Jul 21
Current report (foreign)
6:33am
6-K
EX-99.1
akr1xrgw3av5 14
2 Jul 21
U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
7:14am